{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:33:20Z","timestamp":1763037200929,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10120-018-0853-7","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T11:25:31Z","timestamp":1530098731000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-0372","authenticated-orcid":false,"given":"Yasuhiro","family":"Oono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Shinmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/0360-3016(90)90344-J","volume":"19","author":"J Landry","year":"1990","unstructured":"Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:1357\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1046\/j.1365-2168.2000.01360.x","volume":"87","author":"CH Yoo","year":"2000","unstructured":"Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236\u201342.","journal-title":"Br J Surg"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.bjc.6601896","volume":"91","author":"DH Lim","year":"2004","unstructured":"Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist\u2019s view. Br J Cancer. 2004;91:11\u20137.","journal-title":"Br J Cancer"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337\u201345.","journal-title":"N Engl J Med"},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.3748\/wjg.v19.i38.6383","volume":"19","author":"M Luis","year":"2013","unstructured":"Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araujo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol. 2013;19:6383\u201397.","journal-title":"World J Gastroenterol"},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ctrv.2013.02.001","volume":"39","author":"GV Scagliotti","year":"2013","unstructured":"Scagliotti GV, Novello S, von Pawel J. The emerging role of MET\/HGF inhibitors in oncology. Cancer Treat Rev. 2013;39:793\u2013801.","journal-title":"Cancer Treat Rev"},{"key":"853_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.bulcan.2014.08.001","volume":"102","author":"E Soularue","year":"2015","unstructured":"Soularue E, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull Cancer. 2015;102:324\u201331.","journal-title":"Bull Cancer"},{"key":"853_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12094-011-0637-6","volume":"13","author":"C Gravalos","year":"2011","unstructured":"Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011;13:179\u201384.","journal-title":"Clin Transl Oncol"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7150\/jca.4090","volume":"3","author":"JT Jorgensen","year":"2012","unstructured":"Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer\u2014a systematic analysis of data from the literature. J Cancer. 2012;3:137\u201344.","journal-title":"J Cancer"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s00268-007-9016-4","volume":"31","author":"G Galizia","year":"2007","unstructured":"Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458\u201368.","journal-title":"World J Surg"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","volume":"52","author":"MA Kim","year":"2008","unstructured":"Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738\u201346.","journal-title":"Histopathology"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"7843","DOI":"10.1158\/1078-0432.CCR-08-1064","volume":"14","author":"M Hayashi","year":"2008","unstructured":"Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14:7843\u20139.","journal-title":"Clin Cancer Res"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1158\/1078-0432.CCR-12-1318","volume":"18","author":"M Terashima","year":"2012","unstructured":"Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II\/III gastric cancer. Clin Cancer Res. 2012;18:5992\u20136000.","journal-title":"Clin Cancer Res"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1159\/000011898","volume":"55","author":"K Tsugawa","year":"1998","unstructured":"Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998;55:475\u201381.","journal-title":"Oncology"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/028418601750444204","volume":"40","author":"TJ Huang","year":"2001","unstructured":"Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma\u2014correlation to clinical features. Acta Oncol. 2001;40:638\u201343.","journal-title":"Acta Oncol"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bjc.2012.237","volume":"107","author":"HE Lee","year":"2012","unstructured":"Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107:325\u201333.","journal-title":"Br J Cancer"},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/modpathol.2013.108","volume":"26","author":"SY Ha","year":"2013","unstructured":"Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013;26:1632\u201341.","journal-title":"Mod Pathol"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.28454","volume":"120","author":"X An","year":"2014","unstructured":"An X, Wang F, Shao Q, Wang FH, Wang ZQ, Wang ZQ, et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent\/metastatic gastric cancer after chemotherapy. Cancer. 2014;120:675\u201382.","journal-title":"Cancer"},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10120-015-0471-6","volume":"19","author":"N Fuse","year":"2016","unstructured":"Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016;19:183\u201391.","journal-title":"Gastric Cancer"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","volume":"59","author":"MA Kim","year":"2011","unstructured":"Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822\u201331.","journal-title":"Histopathology"},{"key":"853_CR23","first-page":"57","volume":"32","author":"H Grabsch","year":"2010","unstructured":"Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value\u2014conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57\u201365.","journal-title":"Cell Oncol"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1593\/tlo.12334","volume":"6","author":"F Grillo","year":"2013","unstructured":"Grillo F, Fassan M, Ceccaroli C, Giacometti C, Curto M, Zagonel V, et al. The reliability of endoscopic biopsies in assessing her2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol. 2013;6:10\u20136.","journal-title":"Transl Oncol"},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1245\/s10434-011-1695-2","volume":"18","author":"KC Kim","year":"2011","unstructured":"Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18:2833\u201340.","journal-title":"Ann Surg Oncol"},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797\u2013805.","journal-title":"Histopathology"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.humpath.2015.06.025","volume":"46","author":"C Zhu","year":"2015","unstructured":"Zhu C, Xu J, Li M, Zhao G, Cao H. Heterogeneity of c-Met expression in Chinese gastric cancer patients. Hum Pathol. 2015;46:1901\u20137.","journal-title":"Hum Pathol"},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","volume":"18","author":"AK Nagatsuma","year":"2015","unstructured":"Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18:227\u201338.","journal-title":"Gastric Cancer"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/annonc\/mdx051","volume":"28","author":"F Lordick","year":"2017","unstructured":"Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28:1767\u20131775","journal-title":"Ann Oncol"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10120-013-0239-9","volume":"17","author":"M Aizawa","year":"2014","unstructured":"Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, et al. Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34\u201342.","journal-title":"Gastric Cancer"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457\u20139.","journal-title":"Br J Surg"},{"key":"853_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1746-1596-7-57","volume":"7","author":"K Sotoudeh","year":"2012","unstructured":"Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol. 2012;7:57.","journal-title":"Diagn Pathol"},{"key":"853_CR33","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","volume":"17","author":"M Mitsunaga","year":"2011","unstructured":"Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17:1685\u201391.","journal-title":"Nat Med"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3265-y","volume":"149","author":"K Shimoyama","year":"2015","unstructured":"Shimoyama K, Kagawa S, Ishida M, Watanabe S, Noma K, Takehara K, et al. Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells. Breast Cancer Res Treat. 2015;149:597\u2013605.","journal-title":"Breast Cancer Res Treat"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"e113276","DOI":"10.1371\/journal.pone.0113276","volume":"9","author":"K Sato","year":"2014","unstructured":"Sato K, Choyke PL, Kobayashi H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model. PLoS One. 2014;9:e113276.","journal-title":"PLoS One"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7150\/thno.11559","volume":"5","author":"K Sato","year":"2015","unstructured":"Sato K, Nagaya T, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience. Theranostics. 2015;5:698\u2013709.","journal-title":"Theranostics"},{"key":"853_CR37","doi-asserted-by":"publisher","first-page":"14143","DOI":"10.18632\/oncotarget.7490","volume":"7","author":"K Ito","year":"2016","unstructured":"Ito K, Mitsunaga M, Nishimura T, Kobayashi H, Tajiri H. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging. Oncotarget. 2016;7:14143\u201352.","journal-title":"Oncotarget"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.molonc.2014.01.006","volume":"8","author":"K Sato","year":"2014","unstructured":"Sato K, Watanabe R, Hanaoka H, Harada T, Nakajima T, Kim I, et al. Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Mol Oncol. 2014;8:620\u201332.","journal-title":"Mol Oncol"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acs.bioconjchem.7b00144","volume":"28","author":"K Ito","year":"2017","unstructured":"Ito K, Mitsunaga M, Nishimura T, Saruta M, Iwamoto T, Kobayashi H, et al. Near-infrared photochemoimmunotherapy by photoactivatable bifunctional antibody-drug conjugates targeting human epidermal growth factor receptor 2 positive cancer. Bioconj Chem. 2017;28:1458\u201369.","journal-title":"Bioconj Chem"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1158\/0008-5472.CAN-05-0426","volume":"65","author":"MD Savellano","year":"2005","unstructured":"Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 2005;65:6371\u20139.","journal-title":"Cancer Res"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1365-2559.2011.04017.x","volume":"59","author":"S Lee","year":"2011","unstructured":"Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59:832\u201340.","journal-title":"Histopathology"},{"key":"853_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19:553\u201360.","journal-title":"Gastric Cancer"},{"key":"853_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-018-6138-8","author":"Y Oono","year":"2018","unstructured":"Oono Y, Kuwata T, Takashima K, Yoda Y, Ikematsu H, Shitara K, et al. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surg Endosc. 2018. \n                    https:\/\/doi.org\/10.1007\/s00464-018-6138-8","journal-title":"Surg Endosc"},{"key":"853_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s10120-014-0394-7","volume":"18","author":"Y Nishida","year":"2015","unstructured":"Nishida Y, Kuwata T, Nitta H, Dennis E, Aizawa M, Kinoshita T, et al. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. Gastric Cancer. 2015;18:458\u201366.","journal-title":"Gastric Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-018-0853-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-018-0853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-018-0853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T11:33:47Z","timestamp":1567078427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-018-0853-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s10120-018-0853-7","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"type":"print","value":"1436-3291"},{"type":"electronic","value":"1436-3305"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"5 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yasuhiro Oono, Takeshi Kuwata, Kenji Takashima, Kensuke Shinmura, Keisuke Hori, Yusuke Yoda, Hiroaki Ikematsu, and Tomonori Yano have no conflict of interests or financial ties to disclose. Kohei Shitara reports personal fees from Astellas Pharma, grants and personal fees from Lilly, personal fees from Bristol-Myers Squibb, personal fees from Takeda, personal fees from Pfizer, grants and personal fees from Ono Pharmaceutical, personal fees from Novartis, personal fees from Abbvie, personal fees from Yakult, grants from Dainippon Sumitomo Pharma, grants from MSD, grants from Daiichi Sankyo, grants from Taiho Pharmaceutical, and grants from Chugai Pharma, outside the submitted work. Takahiro Kinoshita reports personal fees from Olympus, Johnson & Johnson, Medtronic, Yakult Pharma, Taiho Pharma, and Eli Lilly, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the medical ethics committee of our hospital (2013-336). Patient informed consent was waived due to the retrospective design of the study. This study was performed in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}